Armodafinil API Manufacturers

Looking for Armodafinil API 112111-43-0?

Description:

Here you will find a list of producers, manufacturers and distributors of Armodafinil. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Armodafinil 

Synonyms:

R-modafinil  

Cas Number:

112111-43-0 

DrugBank number:

DB06413 

Unique Ingredient Identifier:

V63XWA605I

Armodafinil is a type of Psychostimulants

Psychostimulants are a specific subcategory of pharmaceutical Active Pharmaceutical Ingredients (APIs) that have gained significant attention in the medical field. These compounds are known for their stimulating effects on the central nervous system, making them valuable for treating various conditions such as attention deficit hyperactivity disorder (ADHD), narcolepsy, and certain cases of depression.

The primary mechanism of action of psychostimulants involves increasing the levels of certain neurotransmitters in the brain, particularly dopamine and norepinephrine. This heightened neurotransmitter activity results in enhanced cognitive functions, improved focus, and increased alertness. The most commonly prescribed psychostimulants include methylphenidate and amphetamines.

Methylphenidate is a well-known psychostimulant that works by blocking the reuptake of dopamine and norepinephrine, thereby increasing their concentrations in the synaptic cleft. This leads to improved concentration and reduced impulsivity in individuals with ADHD. Similarly, amphetamines stimulate the release of these neurotransmitters while also inhibiting their reuptake.

Psychostimulants are typically administered orally in the form of tablets or capsules, allowing for controlled and sustained release of the medication. These APIs undergo rigorous quality control measures to ensure their purity, potency, and safety.

In conclusion, psychostimulants are a specialized class of pharmaceutical APIs that effectively stimulate the central nervous system, leading to improved cognitive functions and reduced symptoms associated with ADHD, narcolepsy, and certain cases of depression. Their mechanisms of action involve enhancing neurotransmitter activity in the brain, particularly dopamine and norepinephrine. By adhering to strict quality control standards, these psychostimulant APIs provide safe and effective treatment options for patients in need.

Armodafinil (Psychostimulants), classified under Central Nervous System Agents

Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.

CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.

The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.

Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.

• Actavis Group from Iceland, product country of origin Unknown
• Unimark Remedies from India, product country of origin India
• Acura Labs from India, product country of origin India
• Natco Pharma from India, product country of origin India
• Teva API from Israel, product country of origin Unknown
• PLIVA from Czech Republic, product country of origin Croatia
• Lupin from India, product country of origin India
• Piramal Pharma Solutions from India, product country of origin India
• Sigma-Aldrich from United States, product country of origin Unknown
• Mylan from India, product country of origin India

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.